Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib-R-mini-CHOP in elderly patients with newly diagnosed DLBCL
ACTRN12615000551594Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ibrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine and 2 more, sponsored by Australasian Leukaemia & Lymphoma Group. Started Nov 2015; status: completed.
02
Drugs
ibrutinibrituximabcyclophosphamidedoxorubicinvincristine
Beyond the preview
Go deeper on ACTRN12615000551594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000551594.